Strickler, J. H., Cercek, A., Ng, K., Siena, S., André, T., Van Cutsem, E., … Bekaii-Saab, T. (2023). 551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER. In Annals of Oncology (Vol. 34, pp. S411–S412). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.1742

Strickler, J. H., A. Cercek, K. Ng, S. Siena, T. André, E. Van Cutsem, C. Wu, et al. “551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER.” In Annals of Oncology, 34:S411–12. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.1742.

Strickler JH, Cercek A, Ng K, Siena S, André T, Van Cutsem E, et al. 551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER. In: Annals of Oncology. Elsevier BV; 2023. p. S411–2.

Strickler, J. H., et al. “551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S411–12. Crossref, doi:10.1016/j.annonc.2023.09.1742.

Strickler JH, Cercek A, Ng K, Siena S, André T, Van Cutsem E, Wu C, Paulson AS, Hubbard J, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez Fernandez ME, Stecher M, Cronin P, Bieda M, Bekaii-Saab T. 551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER. Annals of Oncology. Elsevier BV; 2023. p. S411–S412.